|
Genzyme makes big money off uncommon diseases. The company's product portfolio focuses on treatments for rare genetic disorders, as well as kidney disease and cancer. One of its main products, Cerezyme, is a leading (and pricey) treatment for Gaucher disease, a rare enzyme-deficiency condition. Founded in 1981, Genzyme has treatments for other enzyme disorders including Fabry disease and Pompe disease. In addition, the company develops gene-based cancer treatment products, renal care and immunological therapies, organ transplant drugs, and orthopedic biosurgery products. The company was acquired by Sanofi for some $20.1 billion in 2011.
|
| | | Contact Information | |
Address: |
500 Kendall St.
Cambridge, MA 02142
| | Phone: | 617-252-7500 | | Fax: | 617-252-7600 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Christopher A. (Chris) Viehbacher
| | • |
CFO:
Marc Esteva
| | • |
SVP Government Relations:
Mary McGrane
|
|
|
Industry Information
| |
Sector: | |
Industry: |
|
|
